• Brandon Capital Partners-backed Aravax secured FDA Fast Track designation for PVX108, its lead immunotherapy for peanut allergy.
• The designation supports an accelerated US development and review pathway, with Phase 2 data expected later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brandon Capital Partners Pty Ltd published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.